The German biotech that shot to fame with a COVID-19 vaccine is now trying to prove it can do the same for cancer. BioNTech enters the year’s most consequential stretch of trading, with the American Society of Clinical Oncology (ASCO) annual meeting in Chicago serving as the proving ground. Investors will be watching closely not just for the clinical verdicts, but for signals on whether the company’s multi-billion-dollar pivot from infectious disease to oncology is on track.
Two oral presentations anchor the company’s ASCO lineup. The first revolves around pumitamig (BNT327), a bispecific immune modulator developed with Bristol Myers Squibb that combines PD-L1 checkpoint inhibition with VEGF-A neutralization. Data from the Phase 2/3 ROSETTA Lung-02 study show encouraging anti-tumor activity in first-line non-small cell lung cancer across a range of PD-L1 expression levels. Crucially, this marks the third global dataset to deliver consistent signals for pumitamig plus chemotherapy, following earlier readouts in small-cell lung cancer and triple-negative breast cancer. The second oral presentation covers gotistobart (BNT316), a CTLA-4 antibody that selectively depletes regulatory T cells in the tumor microenvironment. Phase 2 results from the PRESERVE-004 study demonstrate durable responses and clinically meaningful overall survival data in heavily pre-treated patients with platinum-resistant ovarian cancer, all without chemotherapy.
Beyond the ASCO frenzy, a regulatory milestone is taking shape. BioNTech and partner DualityBio aim to submit a Biologics License Application to the U.S. Food and Drug Administration for Trastuzumab Pamirtecan in 2026, pending regulatory feedback. The antibody-drug conjugate already holds Fast Track and Breakthrough Therapy designations for endometrial cancer, awarded in 2023. Phase 2 data from April showed a confirmed objective response rate of 47.9% across all tested HER2 levels, with median progression-free survival of 8.1 months. A successful filing would mark BioNTech’s first oncology approval in the United States.
Should investors sell immediately? Or is it worth buying BioNTech?
The pipeline is expanding rapidly, but the cost is showing up in the financials. BioNTech now runs more than 25 late-stage clinical studies, including 13 pivotal trials, with six more Phase 3 starts planned for 2026, pushing the total to 15. Seven late-stage data readouts are expected before year-end. The net loss widened to €622 million, with research and development spending climbing to around €652 million, driven primarily by pumitamig and gotistobart. The company reaffirmed its full-year revenue forecast of $2.3 billion to $2.6 billion. A cash pile of $19.6 billion provides ample cushion, supplemented by an ongoing share buyback program of up to $1 billion.
The stock market reflects the uncertainty surrounding the transformation. BioNTech shares closed at €79.50, roughly 22% below the 52-week high of €101.90. Over the past month, the stock has lost about 15% of its value. Despite the near-term weakness, analysts remain broadly constructive: 17 analysts cover the stock, with the majority issuing buy ratings and a consensus price target of $125.45.
US investors face a shortened trading week due to a Monday holiday on Wall Street, leaving a tight window of sessions before the ASCO kickoff on Friday. The four-day event, running from May 29 to June 2, will determine whether the clinical data are strong enough to close the valuation gap. If pumitamig delivers a convincing performance against the Keytruda standard, the conversation around BioNTech’s oncology potential could be reignited. If not, the high cash burn rate will quickly return to the spotlight.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from May 24 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from May 24.
BioNTech: Buy or sell? Read more here...
